COMMUNIQUÉS West-GlobeNewswire

Phase III trial results of novel triple combination pill for hypertension published in The Lancet
18/10/2024
Phase III trial results of novel triple combination pill for hypertension published in The Lancet Novel combination pill significantly reduced blood pressure and improved control rates vs dual therapy, with good [...]
ViaNautis Bio appoints Dr Adi Hoess as Chief Executive Officer
18/10/2024
ViaNautis Bio appoints Dr Adi Hoess as Chief Executive Officer Cambridge UK , 18 October 2024 – ViaNautis Bio (“ViaNautis” or the “Company”), a groundbreaking nanomedicine company at the forefront of genetic therapies, [...]
KFSHRC Leads Healthcare Intelligence in Diagnostics and Patient Care
18/10/2024
RIYADH, Saudi Arabia, Oct. 18, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) is contributing to global healthcare innovation, leveraging artificial intelligence (AI) and [...]
Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement
18/10/2024
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES VANCOUVER, British Columbia, Oct. 18, [...]
Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer
18/10/2024
If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment with Kisqali ® ( [...]
Le KFSHRC présente ses dernières innovations et solutions de santé à l’occasion de la Global Health Exhibition 2024
18/10/2024
RIYAD, Arabie saoudite, 18 oct. 2024 (GLOBE NEWSWIRE) -- Le King Faisal Specialist Hospital and Research Centre (KFSHRC) participera comme principal sponsor (Platine) à l’édition 2024 du Forum mondial de la santé ( [...]
Better Choice Company Chairman Issues Letter to Shareholders as Company Continues to Make Progress Towards the Closing of its SRx Health Acquisition
18/10/2024
Combined company will emerge as a leading global health and wellness company by providing better products and solutions for pets, people, and families Combined 2025 revenue and EBITDA expected to be approximately +$270 [...]
Nxera Pharma to Host R&D Day 2024
18/10/2024
Nxera Pharma Co., Ltd. will hold an R&D Day on 6 November 2024 at 16:30 JST. The meeting will be held virtually via Zoom webinar. Please click here to pre-register for the event. Date : Wednesday, 6 November 2024 [...]
Novo Nordisk A/S: Alhemo® recommended for European approval as first once-daily subcutaneous prophylactic treatment for people living with haemophilia A or B with inhibitors
18/10/2024
Bagsværd, Denmark, 18 October 2024 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending approval of [...]
ITM and NTP Strengthen Global Radioisotope Production Capacities by Renewing their Technology License Agreement and Signing a Manufacturing and Supply Agreement for n.c.a. Lutetium-177
18/10/2024
Extension of 2012 agreement grants NTP the rights to manufacture and distribute non-carrier-added Lutetium-177 (n.c.a. 177 Lu) Companies enter into an additional manufacturing and supply agreement for NTP to produce and [...]
Fortrea publie son premier rapport de Responsabilité Sociale d’Entreprise
18/10/2024
DURHAM, Caroline du Nord, 18 oct. 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq : FTRE), l’un des principaux organismes internationaux de recherche sous contrat (CRO), a annoncé aujourd’hui la publication du premier rapport [...]
Telix Files Form 20-F Registration Statement for Nasdaq ADS
17/10/2024
MELBOURNE, Australia, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces that it has publicly filed a Form 20-F registration statement (Registration Statement) with [...]
Laguna Treatment Center Sets Standard for Veteran Addiction Care in Southern California with New PsychArmor Certification
17/10/2024
ALISO VIEJO, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Laguna Treatment Center is among an elite group of addiction treatment providers who have earned Veteran Ready status from PsychArmor, a leader in military culture [...]
Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM
17/10/2024
Independent Data Safety and Monitoring Board Endorsed Dose Escalation and Broadening of Eligibility Criteria; Cohort 2 Now Enrolling Initial Data from Cohort 1 to be Reported in December 2024 Highlights Recently [...]
Profound Medical to Release Third Quarter 2024 Financial Results on November 7 – Conference Call to Follow
17/10/2024
TORONTO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free [...]
LifeStance to Host Third Quarter 2024 Earnings Conference Call on November 7, 2024
17/10/2024
SCOTTSDALE, Ariz., Oct. 17, 2024 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (NASDAQ: LFST), one of the nation’s largest providers of outpatient mental health care, will issue its third quarter 2024 earnings [...]
Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder
17/10/2024
Phase 2a study demonstrated rapid and substantial decrease in depressive symptoms SPN-820 was well-tolerated with few adverse events SPN-820 is a novel, first-in-class intracellular modulator of mTORC1 for the treatment [...]
Sight Sciences to Report Third Quarter Financial Results on November 7, 2024
17/10/2024
MENLO PARK, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, [...]
Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial
17/10/2024
Clinical Complete Responses Observed in 4 out of 5 Patients in Subset of Patients with Low Grade Disease; Evidence of Bladder Urothelial Field Effect in Non-Target Tumors Favorable Safety Profile Observed; Only Grade 1 [...]

Pages